Sentinel lymph node biopsy in pregnant women with breast cancer

Annals of Surgical Oncology

Volumn 21, Issue 8, 2014, Pages 2506-2511

  Gropper, Adrienne B ^a   Calvillo, Katherina Zabicki ^a   Dominici, Laura ^a   Troyan, Susan ^a   Rhei, Esther ^a   Economy, Katherine E ^a   Tung, Nadine M ^b   Schapira, Lidia ^c   Meisel, Jane L ^a   Partridge, Ann H ^a   Mayer, Erica L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; METHYLENE BLUE; PROGESTERONE RECEPTOR; TECHNETIUM 99M; TECHNETIUM SULFUR COLLOID TC 99M; COLORING AGENT;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLEFT PALATE; DISTANT METASTASIS; FEMALE; FETAL WELL BEING; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; LIVE BIRTH; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PATIENT SAFETY; PREGNANT WOMAN; PRIMARY TUMOR; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SENTINEL LYMPH NODE BIOPSY; THIRD TRIMESTER PREGNANCY; BREAST NEOPLASMS; DIAGNOSTIC USE; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS;

ADULT; BREAST NEOPLASMS; COLORING AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; METHYLENE BLUE; NEOPLASM STAGING; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 84905095855     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3718-2     Document Type: Article

References (32)

1. Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst. 2008;100:462-474.
2. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-933.
3. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600.
4. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569-575.
5. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-553. (Pubitemid 36951366)
6. Guidroz JA, Scott-Conner CE, Weigel RJ. Management of pregnant women with breast cancer. J Surg Oncol. 2011;103:337-340.
7. Rodriguez AO, Chew H, Cress R, Xing G, McElvy S, Danielsen B, Smith L. Evidence of poorer survival in pregnancy-associated breast cancer. Obstet Gynecol. 2008;112:71-78.
8. Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer. 2006;106:237-246. (Pubitemid 43100430)
9. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94:2542-2551. (Pubitemid 34478066)
10. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703-7720. (Pubitemid 46291835)
11. Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78-83.
12. Spanheimer PM, Graham MM, Sugg SL, Scott-Conner CE, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol. 2009;16:1143-1147.
13. Dubernard G, Garbay JR, Rouzier R, Delaloge S. Safety of sentinel node biopsy in pregnant patients. Ann Oncol. 2005;16:987;987-988. (Pubitemid 40903927)
14. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg. 2003;138:91-98; discussion 99.
15. Meisel JL, Economy KE, Calvillo KZ, et al. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. Springerplus. 2013;2:297.
16. Mondi MM, Cuenca RE, Ollila DW, Stewart JH 4th, Levine EA. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol. 2007;14:218-221. (Pubitemid 44954292)
17. Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14:250-254. (Pubitemid 351678056)
18. Andtbacka RH, Donaldson MR, Bowles TL, et al. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013;20:689-696.
19. Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99 mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006;47:1202-1208. (Pubitemid 47544916)
20. Gentilini O, Cremonesi M, Trifiro G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348-1351. (Pubitemid 39295022)
21. Keleher A, Wendt R 3rd, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004;10:492-495. (Pubitemid 39524981)
22. Cimmino VM, Brown AC, Szocik JF, Pass HA, Moline S, De SK, et al. Allergic reactions to isosulfan blue during sentinel node biopsy: a common event. Surgery. 2001;130:439-442. (Pubitemid 32868455)
23. Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg . 2001;182:393-398. (Pubitemid 33079094)
24. Masannat YA, Hanby A, Horgan K, Hardie LJ. DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. J Surg Res. 2009;154:234-238.
25. Pruthi S, Haakenson C, Brost BC, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg. 2011;201:70-75.
26. Cody HS 3rd, Fey J, Akhurst T, et al. Complementarity of blue dye and isotope in sentinel node localization for breast cancer: univariate and multivariate analysis of 966 procedures. Ann Surg Oncol. 2001;8:13-19. (Pubitemid 32126820)
27. Pesek S, Ashikaga T, Krag LE, Krag D. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. World J Surg. 2012;36:2239-2251.
28. Keleher AJ, Theriault RL, Gwyn KM, et al. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002;194:54-64. (Pubitemid 34044875)
29. Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013;31:2532-2539.
30. Theriault RL, Litton JK. Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know? J Clin Oncol. 2013;31:2521-2522.
31. Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98:1055-1060. (Pubitemid 37022108)
32. Rutgers EJ, Donker M, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial [abstract no. LBA1001]. J Clin Oncol. 2013;31 Suppl.